E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Respiratory tract infections in children aged between 6 months and 12 years |
|
E.1.1.1 | Medical condition in easily understood language |
Chest infections in children aged 6 months to 12 years |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10066740 |
E.1.2 | Term | Acute respiratory tract infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10024968 |
E.1.2 | Term | Lower respiratory tract infection |
E.1.2 | System Organ Class | 10021881 - Infections and infestations |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Our aim is to provide evidence to inform the use of antibiotics for the management of chest infections in children. The objectives are:
1) To estimate the effectiveness of amoxicillin overall and in key clinical subgroups of children presenting with uncomplicated (non-pneumonic) lower respiratory tract infection in primary care
2) To estimate the cost-effectiveness of antibiotics overall and in key clinical subgroups of children presenting with uncomplicated lower respiratory tract infection in primary care
3) To explore the estimates of effectiveness according to key pathophysiological subgroups ( the presence of bacterial pathogens; raised C reactive protein measurement or white cell count; the presence of clinically undetected consolidation on X ray; oximetry; lung function) |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
OBSERVATIONAL STUDY FOR THOSE REFUSING RANDOMISATION Some parents will decline randomisation, either due to concern about getting antibiotics or not getting antibiotics. The main concern for the trial data is that due to selection bias the trial may end up addressing the milder end of the clinical spectrum. Hence we propose, as in our previous adult trial, that those not consenting to randomisation are offered participation in an observational study where the same outcomes are collected so that the characteristics and outcomes can be compared with trial participants. We have allowed for up to 30% additional parents being willing to undertake the observational trial.
NESTED QUALITATIVE STUDY AIMS (1) Prior to the start of the study itself, a small student study was undertaken to explore a range of parent (and child/patient) views to aid the design of study procedures, to help optimize the acceptability of procedures once the trial is operational (REC ref: 14/WA/1226. A second part of this is (2) To explore a range of parent (and child/patient) views on study participation, seeking to understand positive and negative experiences from start to finish.
TIMING (1) Has already taken place in the months prior to the study commencement/randomization. (2) Will take place once participants have been randomized and participated.
METHODS Semi-structured in-depth interviews will be used, but will be flexible to permit parents to speak freely on topics they deem to be relevant to ensure key emerging issues are captured. A subtle realist approach will be employed throughout the project to help represent participants’ views.
SAMPLE A purposive sampling approach will be designed to elicit views of a range of parents (and children where appropriate) (including a mix of men and women/boys and girls). 1. A total of 16 interviews took place which was deemed to be sufficient to gather detailed feedback on parent (children/patients) views to help design the trial procedures. 2. Between 15 and 30 interviews should be adequate to represent the views of a range of parents(children/patients) following participation. Additional interviews will be conducted if saturation has not been reached.
ANALYSIS We will follow the stages of Braun and Clarke’s thematic analysis, assisted by NVivo computerized analysis software. Analysis will aim to identify themes to help fulfil aims 1 and 2 whilst remaining flexible and open to emerging findings.
QUALITY Standard methodological strategies will be employed to help safeguard rigour and ensure we produce trustworthy, plausible, and relevant findings. These will include careful purposive sampling, a clear exposition of methods (including field notes, and audio recording of interviews and accurate transcription of interviews, regular discussion between the fieldworker and senior qualitative researcher (including double coding/discussion of codes). Negative case analysis will help to refine analysis/safeguard against premature completion and the researcher will be tutored in the importance of a ‘reflexive’ sensitivity to the relationship between the researcher and research process.
|
|
E.3 | Principal inclusion criteria |
Children between 6 months and twelve years old presenting with an acute lower respiratory infection (LRTI), defined as an acute cough as the predominant symptom, judged by the GP to be infective in origin (any of: a systemic symptom (diarrhoea, fever, raised temperature), coryza, sputum production, wheezing, sore throat, earache), lasting <21 days, and with other symptoms or signs localising to the lower tract (shortness of breath, sputum - or more likely in this age group audible secretions suggesting sputum), Parent/guardian willing and able to be contacted for follow up and complete symptom diary for up to 28 days.
|
|
E.4 | Principal exclusion criteria |
The cough is judged by the clinician to have a non-infectious aetiology (e.g. hayfever or asthma) or almost certain viral aetiology (croup, where antibiotics are not commonly prescribed); immune-compromised; and antibiotic use in previous 30 days. For the trial, suspected pneumonia based on clinical examination or being very severely ill as judged by the GP is an exclusion but such children can still enter the observational study. In addition only one child from each household will be recruited. Additionally children will be eligible for trial but eligible for cohort study if the child is immune-compromised, has a history of antibiotic use in previous 30 days, has a clinical diagnosis of pneumonia, has had previous pneumonia, has focal rales, has a low oxygen saturation (<92%), has severe tachypnoea (clinician judged), has Severe Asthma requiring long-term maintenance oral steroids (as defined in the British Thoracic Society Step 5).
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary outcome will be mean duration of symptoms rated moderately bad or worse recorded for up to 28 days until symptoms settle in a validated daily diary. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Severity of symptoms Side effects Quality of Life using the EQ5-D Worsening symptoms or complications Health Care resource use |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Severity of symptoms in the first 2-4 days after seeing the doctor Side effects during the 28 days Quality of Life using the EQ5-D - on days 1,3,7,14,28 Worsening symptoms or complications during the 28 days |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 11 |
E.8.9.1 | In the Member State concerned days | 31 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 11 |
E.8.9.2 | In all countries concerned by the trial days | 31 |